1004 related articles for article (PubMed ID: 11682953)
1. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
[TBL] [Abstract][Full Text] [Related]
2. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.
Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
East Afr Med J; 2001 Feb; 78(2):84-9. PubMed ID: 11682952
[TBL] [Abstract][Full Text] [Related]
3. Leishmania transmission-blocking vaccines: a review.
Tonui WK
East Afr Med J; 1999 Feb; 76(2):93-6. PubMed ID: 10442130
[TBL] [Abstract][Full Text] [Related]
4. Effects of anti-Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae).
Anjili C; Langat B; Ngumbi P; Mbati PA; Githure J; Tonui WK
East Afr Med J; 2006 Feb; 83(2):72-8. PubMed ID: 16708877
[TBL] [Abstract][Full Text] [Related]
5. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.
Jaafari MR; Ghafarian A; Farrokh-Gisour A; Samiei A; Kheiri MT; Mahboudi F; Barkhordari F; Khamesipour A; McMaster WR
Vaccine; 2006 Jul; 24(29-30):5708-17. PubMed ID: 16740346
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
7. Vaccinations with live-attenuated Leishmania major promastigotes and challenge infection with L. major in BALB/c mice.
Onyalo JA; Mwala DM; Anjili CO; Orago AS; Tonui WK
East Afr Med J; 2005 Apr; 82(4):193-7. PubMed ID: 16122087
[TBL] [Abstract][Full Text] [Related]
8. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
Bretscher PA; Ogunremi O; Menon JN
Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
[TBL] [Abstract][Full Text] [Related]
9. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.
Al-Wabel MA; Tonui WK; Cui L; Martin SK; Titus RG
Am J Trop Med Hyg; 2007 Dec; 77(6):1060-5. PubMed ID: 18165522
[TBL] [Abstract][Full Text] [Related]
10. Leishmania major infections in Phlebotomus duboscqi fed on murine models immunized with L. major subcellular antigens and sandfly gut antigens.
Mbati PA; Anjili CO; Odongo S; Ogaja P; Tonui W
Onderstepoort J Vet Res; 2000 Mar; 67(1):57-63. PubMed ID: 10843323
[TBL] [Abstract][Full Text] [Related]
11. Experimental immunization against cutaneous leishmaniasis using Leishmania major subcellular fractions alone or in combination with Phlebotomus duboscqi gut antigens.
Mbati PA; Anjili CO; Lugalia R; Mwanyumba P; Tonui WK; Robert LL; Githure JI
East Afr Med J; 1995 Aug; 72(8):519-22. PubMed ID: 7588148
[TBL] [Abstract][Full Text] [Related]
12. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
[TBL] [Abstract][Full Text] [Related]
13. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
14. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
16. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan.
Pinheiro RO; Pinto EF; de Matos Guedes HL; Filho OA; de Mattos KA; Saraiva EM; de Mendonça SC; Rossi-Bergmann B
Vaccine; 2007 Mar; 25(14):2716-22. PubMed ID: 16814903
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge.
Menon JN; Bretscher PA
Eur J Immunol; 1996 Jan; 26(1):243-9. PubMed ID: 8566074
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
19. [Protective effects of leishmanial antigens against Leishmania infantum infection in Lagurus lagurus].
Chai J; Chang KP; Zuo X; Yan L; Hou Y; Zhang S; Ruziguli ; Jiang W; Zhang L
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1999; 17(4):237-40. PubMed ID: 12563775
[TBL] [Abstract][Full Text] [Related]
20. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
